Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
Mesoblast shares fell -4.45% in the first hour of trades on Tuesday as the company announced it has to resubmit an application to the FDA.
ROK
0.00%
$2.75
![](/images/icons/chart-icon.png)
ROCK BUILDING SOCIETY LIMITED (THE) - News & Media
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No News & Media currently available.